(Q37689194)

22 August 2017

title

Patented small molecule inhibitors of p53-MDM2 interaction (English)

1 reference

22 August 2017

0 references

Jinxia Deng

1

1 reference

22 August 2017

Raveendra Dayam

series ordinal

2

1 reference

22 August 2017

Nouri Neamati

series ordinal

3

1 reference

22 August 2017

language of work or name

English

0 references

publication date

1 February 2006

1 reference

Expert Opinion on Therapeutic Patents

22 August 2017

published in

1 reference

22 August 2017

volume

16

1 reference

22 August 2017

issue

2

1 reference

22 August 2017

page(s)

165-188

1 reference

Molecular analysis and chromosomal mapping of amplified genes isolated from a transformed mouse 3T3 cell line

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.2.165

The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.2.165

Amplification of a gene encoding a p53-associated protein in human sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.2.165

MDM-2 oncoprotein overexpression, p53 gene mutation, and VEGF up-regulation in angiosarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.2.165

The p53-Mdm2 pathway: targets for the development of new anticancer therapeutics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.2.165

MDM2 and human malignancies: expression, clinical pathology, prognostic markers, and implications for chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.2.165

MDM2 is a central node in the p53 pathway: 12 years and counting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.2.165

High levels of the MDM2 oncogene in paediatric rhabdomyosarcoma cell lines may confer multidrug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.2.165

Role of MDM2 overexpression in doxorubicin resistance of breast carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.2.165

Hypoxia enhances metastatic efficiency by up-regulating Mdm2 in KHT cells and increasing resistance to apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.2.165

p53-independent activities of MDM2 and their relevance to cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.2.165

The p53 proto-oncogene can act as a suppressor of transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.2.165

Small molecule antagonists of the MDM2 oncoprotein as anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.2.165

Regulation of p53 function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.2.165

The role of p53 in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.2.165

p53 mutations in human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.2.165

Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.2.165

MDM2--master regulator of the p53 tumor suppressor protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.2.165

Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.2.165

Hydrophobic side-chain size is a determinant of the three-dimensional structure of the p53 oligomerization domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.2.165

Refined solution structure of the oligomerization domain of the tumour suppressor p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.2.165

Solution structure of the tetrameric minimum transforming domain of p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.2.165

Solution structure of a dynein motor domain associated light chain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.2.165

Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.2.165

Crystallization and structure solution of p53 (residues 326-356) by molecular replacement using an NMR model as template

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.2.165

Crystal structure of a superstable mutant of human p53 core domain. Insights into the mechanism of rescuing oncogenic mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.2.165

Structures of p53 cancer mutants and mechanism of rescue by second-site suppressor mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.2.165

Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.2.165

Functions of the MDM2 oncoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.2.165

Molecular biology. Getting p53 out of the nucleus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.2.165

Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.2.165

Molecular characterization of the hdm2-p53 interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.2.165

Binding of p53-derived ligands to MDM2 induces a variety of long range conformational changes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.2.165

p53 alpha-Helix mimetics antagonize p53/MDM2 interaction and activate p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.2.165

Chalcone derivatives antagonize interactions between the human oncoprotein MDM2 and p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.2.165

Isolation and structure elucidation of Chlorofusin, a novel p53-MDM2 antagonist from a Fusarium sp.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.2.165

Design, synthesis, and evaluation of novel boronic-chalcone derivatives as antitumor agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.2.165

In vivo activation of the p53 pathway by small-molecule antagonists of MDM2

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.2.165

Discovery and cocrystal structure of benzodiazepinedione HDM2 antagonists that activate p53 in cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.2.165

Inhibiting the p53-MDM2 interaction: an important target for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.2.165

p53-Mdm2--the affair that never ends

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.2.165

Synthesis and SAR of novel 4,5-diarylimidazolines as potent P2X7 receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.2.165

p53 Activation by small molecules: application in oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.2.165

Design, synthesis, and evaluation of mixed imine-amine pyrrolobenzodiazepine dimers with efficient DNA binding affinity and potent cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.2.165

Synthesis and DNA binding affinity of novel A-C8/C-C2-exo unsaturated alkoxyamido-linked pyrrolo[2,1-c][1,4]benzodiazepine dimers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.2.165

Design, synthesis, and evaluation of a novel pyrrolobenzodiazepine DNA-interactive agent with highly efficient cross-linking ability and potent cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.2.165

Design, synthesis and biological activity of YM-60828 derivatives. Part 2: potent and orally-bioavailable factor Xa inhibitors based on benzothiadiazine-4-one template

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.2.165

Design, synthesis, and evaluation of new noncross-linking pyrrolobenzodiazepine dimers with efficient DNA binding ability and potent antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.2.165

Structure-based design, synthesis, and biological evaluation of novel 1,4-diazepines as HDM2 antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.2.165

N-Arylpiperazine-1-carboxamide derivatives: a novel series of orally active nonsteroidal androgen receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.2.165

Synthesis and pharmacological evaluation of novel arylpiperazine derivatives as nonsteroidal androgen receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.2.165

Synthesis and antibacterial activity of 2-(4-substituted phenyl)-3(2H)-isothiazolones.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.2.165

Synthesis and biological evaluation of piperazine-based derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.2.165

Structure-activity relationship for aryl and heteroaryl boronic acid inhibitors of hormone-sensitive lipase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.2.165

Design, synthesis, and biological evaluation of aminoboronic acids as growth-factor receptor inhibitors of EGFR and VEGFR-1 tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.2.165

Structure-based design of potent non-peptide MDM2 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.2.165

Inhibition of protein-protein association by small molecules: approaches and progress

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.2.165

Designed molecules that fold to mimic protein secondary structures

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.2.165

Synthesis of pipecolic acid-based spiro bicyclic lactam scaffolds as beta-turn mimics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.2.165

Design, synthesis, and conformational analysis of eight-membered cyclic peptidomimetics prepared using ring closing metathesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.2.165

Systematic study of the synthesis of macrocyclic dipeptide beta-turn mimics possessing 8-, 9-, and 10- membered rings by ring-closing metathesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.2.165

Effect of sequence on peptide geometry in 5-tert-butylprolyl type VI beta-turn mimics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.2.165

Toward proteomimetics: terphenyl derivatives as structural and functional mimics of extended regions of an alpha-helix

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.2.165

Protein ubiquitination involving an E1-E2-E3 enzyme ubiquitin thioester cascade

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.2.165

Themes and variations on ubiquitylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.2.165

Differentiation of Hdm2-mediated p53 ubiquitination and Hdm2 autoubiquitination activity by small molecular weight inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.2.165

Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.2.165

Reactivation of mutant p53 and induction of apoptosis in human tumor cells by maleimide analogs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.2.165

Small molecules that reactivate mutant p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.2.165

Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.2.165

PRIMA-1(MET) synergizes with cisplatin to induce tumor cell apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.16.2.165

10.1517/13543776.16.2.165

21 January 2018

Identifiers

DOI

1 reference

22 August 2017

1 reference